Substrate spectrum extension of PenA in Burkholderia thailandensis with a single amino acid deletion, Glu168del

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 4005-4008

  Yi, Hyojeong ^a   Kim, Karan ^a   Cho, Kwang Hwi ^b   Jung, Oksung ^b   Kim, Heenam Stanley ^a  

^a Korea University College of Medicine   (South Korea)

^b Soongsil University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE; BETA LACTAMASE PENA; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; MEROPENEM; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BURKHOLDERIA; BURKHOLDERIA THAILANDENSIS; ENZYME ACTIVE SITE; ENZYME SUBSTRATE; GENE DELETION; GENE SEQUENCE; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; BURKHOLDERIA; CEFTAZIDIME; SEQUENCE DELETION;

EID: 84862552432     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00598-12     Document Type: Article

References (26)

1. Ambler RP, et al. 1991. A standard numbering scheme for the class A beta-lactamases. Biochem. J. 276(Pt 1):269-270.
2. Bonacorsi S, Fitoussi F, Lhopital S, Bingen E. 1999. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 43:213-217.
3. Brett PJ, DeShazer D, Woods DE. 1998. Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species. Int. J. Syst. Bacteriol. 48(Pt 1):317-320.
4. Cheng AC, Currie BJ. 2005. Melioidosis: epidemiology, pathophysiology, and management. Clin. Microbiol. Rev. 18:383-416.
5. Dance DAB, Wuthiekanun V, Chaowagul W, White NJ. 1989. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J. Antimicrob. Chemother. 24:295-309.
6. Friedrichs MS, et al. 2009. Accelerating molecular dynamic simulation on graphics processing units. J. Comput. Chem. 30:864-872.
7. Jelsch C, Mourey L, Masson JM, Samama JP. 1993. Crystal structure of Escherichia coli TEM1beta-lactamase at 1.8Aresolution. Proteins 16:364-383.
8. Joyce LF, Downes J, Stockman K, Andrew JH. 1992. Comparison of five methods, including the PDM Epsilometer test (E test), for antimicrobial susceptibility testing of Pseudomonas aeruginosa. J. Clin. Microbiol. 30:2709-2713.
9. Keen NT, Tamaki S, Kobayashi D, Trollinger D. 1988. Improved broad-host-range plasmids for DNA cloning in Gram-negative bacteria. Gene 70:191-197.
10. Leitão JH, et al. 2010. Pathogenicity, virulence factors, and strategies to fight against Burkholderia cepacia complex pathogens and related species. Appl. Microbiol. Biotechnol. 87:31-40.
11. Matagne A, Lamotte-Brasseur J, Frere JM. 1998. Catalytic properties of class A beta-lactamases: efficiency and diversity. Biochem. J. 330:581-598.
12. Petrella S, Clermont D, Casin I, Jarlier V, Sougakoff W. 2001. Novel class A β-lactamase Sed-1 from Citrobacter sedlakii: genetic diversity of β-lactamases within the Citrobacter genus. Antimicrob. Agents Chemother. 45:2287-2298.
13. Poirel L, Rodriguez-Martinez J-M, Plesiat P, Nordmann P. 2009. Naturally occurring class A beta-lactamases from the Burkholderia cepacia complex. Antimicrob. Agents Chemother. 53:876-882.
14. Raquet X, et al. 1994. TEM beta-lactamase mutants hydrolysing third-generation cephalosporins: a kinetic and molecular modelling analysis. J. Mol. Biol. 244:625-639.
15. Rholl DA, et al. 2011. Molecular investigations of PenA-mediated β-lactam resistance in Burkholderia pseudomallei. Front. Microbiol. 2:139. doi:10.3389/fmicb.2011.00139.
16. Saika T, Kobayashi I, Hasegawa M, Nishida M. 2002. Antimicrobial resistance and DNA-fingerprinting pattern of Burkholderia cepacia blood isolates. J. Infect. Chemother. 8:341-344.
17. Sam IC, See KH, Puthucheary SD. 2009. Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei. J. Clin. Microbiol. 47:1556-1558.
18. Sarovich DS, et al. 2012. Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia. PLoS One 7:e30789. doi:10.1371/journal.pone.0030789.
19. Simm AM, Baldwin AJ, Busse K, Jones DD. 2007. Investigating protein structural plasticity by surveying the consequence of an amino acid deletion from TEM-1 β-lactamase. FEBS Lett. 581:3904-3908.
20. Song H, et al. 2010. The early stage of bacterial genome-reductive evolution in the host. PLoS Pathog. 6:e1000922. doi:10.1371/journal.ppat. 1000922.
21. Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD. 2004. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J. Antimicrob. Chemother. 54:1134-1138.
22. Tribuddharat C, Moore RA, Baker P, Woods DE. 2003. Burkholderia pseudomallei class a beta-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition. Antimicrob. Agents Chemother. 47:2082-2087.
23. Vakulenko SB, Toth M, Taibi P, Mobashery S, Lerner SA. 1995. Effects of Asp-179 mutations in TEMpUC19 beta-lactamase on susceptibility to beta-lactams. Antimicrob. Agents Chemother. 39:1878-1880.
24. Wang X, Minasov G, Shoichet BK. 2002. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J. Mol. Biol. 320:85-95.
25. Wong W-T, et al. 2011. Increased structural flexibility at the active site of a fluorophore-conjugated β-lactamase distinctively impacts its binding toward diverse cephalosporin antibiotics. J. Biol. Chem. 286:31771-31780.
26. Wuthiekanun V, Peacock SJ. 2006. Management of melioidosis. Expert Rev. Anti Infect. Ther. 4:445-455.